Corporate Overview

Over 45 million people in the U.S. have a substance use, addictive, or eating disorder. The National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH), describes these disorders as chronic relapsing brain diseases, which burden society at both the individual and community levels. Opiant is a specialty pharmaceutical company developing treatments for substance use, addictive, and eating disorders.

Our Foundation

Opiant was co-founded by the late Dr. David Sinclair based on his pioneering research demonstrating that opioid antagonists could be used as a symptom-driven treatment for alcoholism. Our opioid antagonist nasal spray treatments are a symptom-driven treatment for substance use, addictive, and eating disorders.

Science and Technology

With our innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in the substance use, addictions, and eating disorders treatment markets. Currently, Opiant is developing opioid antagonist nasal sprays for the treatment of opioid overdose, cocaine use disorder, and binge eating disorder. Our breakthrough naloxone (opioid antagonist) nasal spray treatment is FDA approved for the treatment of opioid overdose in collaboration with our partner, Adapt Pharma. Narcan® Nasal Spray